.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Post-Conference Perspectives: Advances in Chronic and Acute Graft-versus-Host Disease

EP. 1: Treatment Landscape of Graft-Versus-Host Disease

December 21st 2019

EP. 2: Approval of Ruxolitinib: Steroid-Refractory Acute GVHD

December 21st 2019

EP. 3: Clinical Trials of Itacitinib for Chronic and Acute GVHD

December 21st 2019

EP. 4: Posttransplant Cyclophosphamide for GVHD

December 21st 2019

EP. 5: The Future of Treating GVHD

December 21st 2019

EP. 6: Historical Management of Graft-Versus-Host Disease

December 21st 2019

EP. 7: Ruxolitinib: Treatment of Steroid-Refractory Acute GVHD

December 21st 2019

EP. 8: Itacitinib Clinical Trials for Chronic and Acute GVHD

December 21st 2019

EP. 9: Novel-Based Approaches in Treating GVHD

December 21st 2019

EP. 10: Post-Transplant Cyclophosphamide and Unmet Needs in GVHD

December 21st 2019